Price Elasticity - PMS

Hello:

Please take a moment and answer the short survey on drug development. Your participation in this study is completely voluntary. It will take approximately 5-10 minutes to complete the questionnaire.

Your answers will help our clients better serve the industry and will be kept confidential. You will be given a chance to enter the drawing at the end of the survey. This is optional. Thank you for your time and consideration.

Please start with the survey now by clicking on the Continue button below.

Please select the level of screening that most closely defines your group's or your institution's strategy surrounding Polymorph Screening

We screen early (pre-formulation) routinely

We screen when we have a problem

Other

We only screen when the compound leaves P1 clinical trials

We screen heavily at all stages of development

We screen early for polymorphism and late (PIII) for intellectual property.

It's a waste of time, we use our money for other development needs

We routinely search for co-crystals as part of our solid form development program

Yes

Not sure

When considering outsourcing solid-state development (polymorph, salt, co-crystal, etc) our institution would consider (check all that apply)

I would classify my insitution as:

Biotech company

Contract Manufacturer

Medium Size Pharamceuticla Company

Small Pharmaceutical Comapny

Large Pharmaceutical Company

Academic Institution

Virtual Pharmaceutical

I would expect to pay X$ for a preliminary (early) polymorph screen:

How many solid-state development projects do you or your institution outsource yearly?

How many conditions (or experiments) do you feel are necessary to conduct a thorough polymorph screen whereby you have a reasonable degree of confidence you have found most relevant forms?

I believe high-throughput (HT) solvent-based screening is the best method for finding all relevant solid forms. Please select the statement THAT MOST CLOSELY MATCHES YOUR BELIEF

Agree, there's no need to do other types of experiments

Somewhat Agree, but we do minimal additional other experiments

Somewhat Agree, but we do a large mix of experiments in addition

Neither Agree nor Disagree

Somewhat Disagree, but some HT experiments are useful

Somewhat Disagree, we do 50% HT solvent-based, 50% alternative methods

Disagree, we do everything manually

* When we select a solid-state screening/selection vendor for polymorph, salt, or co-crystal work we do so by (rank in order of importance, 1 being most important, 6 being least important)

Capacity, time line of execution
Corporate selects vendors for us
Number/diversity of capabilites
Reputation
Price
Past experience

* I (or my insitution) need the most help with (rank in order of need, 1 being greatest need, 6 being least need)

Lifecycle and IP management
Formulation Development / Excipient Compatibility
Amorphous material development
Solid-state development (polymorph, salt, cocrystal)
Routine analytical chemistry
Consistent API maufacturing under cGMP

I'd like to be entered into the drawing (please include name, institution, and phone below). If you do not wish to enter, simply do not answer this question.